A condition involving excess fat buildup in the liver is grossly underdiagnosed in the United States, according to an analysis of Medicare claims data. The condition, called nonalcoholic fatty liver disease (NAFLD), is often associated with obesity and is not related to alcohol consumption.
In the Alimentary Pharmacology & Therapeutics analysis of information on 10,826,456 adults, the prevalence of NAFLD was 5.7%. NAFLD progressed to the more serious liver disease called cirrhosis in 39% of patients with NAFLD over 8 years of follow-up. Cardiovascular disease, kidney impairment, high cholesterol, and diabetes were linked with higher risks of disease progression.
“The study provides us with evidence regarding the real world natural history of NAFLD and long-term clinical outcomes,” said lead author Rohit Loomba, MBBS, of the University of California, San Diego.
Additional Information
Link to Study: https://onlinelibrary.wiley.com/doi/full/10.1111/apt.15679
About Journal
Alimentary Pharmacology & Therapeutics is an international journal of gastroenterology and hepatology.
The journal accepts systematic reviews, meta-analyses, randomised controlled trials and original papers concerned with Gastroenterology and Hepatology.
AP&T is particularly interested in therapies and diagnostics, including all aspects of translation from bench to bedside: identification of novel therapeutic targets, epidemiology, clinical trials, drug safety and meta-analyses.
About Wiley
Wiley drives the world forward with research and education. Through publishing, platforms and services, we help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. For more than 200 years, we have delivered consistent performance to all of our stakeholders. The Company's website can be accessed at www.wiley.com.